Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the debt to assets ratio high or low?
The debt to assets ratio of 23.57% is in line with its 5-year average of 25.15%, near the low end of its 5-year range (12.48%–176.36%).
As of the fiscal period ended Tuesday, June 30, 2026. 70.75% below its 12-month average of 80.59%.
Reported quarterly debt to assets ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 23.57%.
DEBT TO ASSETS RATIO
23.57%
DEBT TO ASSETS RATIO AVG TTM
80.59%
DEBT TO ASSETS RATIO AVG 3Y
69.96%
DEBT TO ASSETS RATIO AVG 5Y
25.15%
DEBT TO ASSETS RATIO AVG 10Y
40.96%
DEBT TO ASSETS RATIO AVG 15Y
54.31%
DEBT TO ASSETS RATIO AVG 20Y
70.33%
CURRENT VS TTM AVG
-70.75%
CURRENT VS 3Y AVG
-66.30%
CURRENT VS 5Y AVG
-6.27%
CURRENT VS 10Y AVG
-42.45%
CURRENT VS 15Y AVG
-56.60%
CURRENT VS 20Y AVG
-66.48%
SECTOR MEDIAN · HEALTHCARE
0.11%
median of 465 covered companies
CURRENT VS SECTOR MEDIAN
+21329.64%
vs the sector median at left
Agenus Inc.
Market Cap
$363.54M
Debt to Assets Ratio
23.57%
TTM Avg
80.59%
3Y Avg
69.96%
5Y Avg
25.15%
Market Cap
$361.64M
Debt to Assets Ratio
0.38%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$366.39M
Debt to Assets Ratio
0.19%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$368.91M
Debt to Assets Ratio
0.00%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$373.40M
Debt to Assets Ratio
0.25%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$348.59M
Debt to Assets Ratio
0.03%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$345.48M
Debt to Assets Ratio
0.74%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$339.15M
Debt to Assets Ratio
0.10%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | DEBT TO ASSETS RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Agenus Inc. (AGEN) | $363.54M | 23.57% | 80.59% | 69.96% | 25.15% |
| Opus Genetics, Inc. (IRD)vs › | $361.64M | 0.38% | N/A | N/A | N/A |
| Enanta Pharmaceuticals, Inc. (ENTA)vs › | $366.39M | 0.19% | N/A | N/A | N/A |
| Fennec Pharmaceuticals Inc. (FENC)vs › | $368.91M | 0.00% | N/A | N/A | N/A |
| Canopy Growth Corporation (CGC)vs › | $373.40M | 0.25% | N/A | N/A | N/A |
| Embecta Corp. (EMBC)vs › | $348.85M | 1.19% | N/A | N/A | N/A |
| Artiva Biotherapeutics, Inc. (ARTV)vs › | $348.59M | 0.03% | N/A | N/A | N/A |
| ClearPoint Neuro, Inc. (CLPT)vs › | $345.48M | 0.74% | N/A | N/A | N/A |
| Cabaletta Bio, Inc. (CABA)vs › | $339.15M | 0.10% | N/A | N/A | N/A |
| C4 Therapeutics, Inc. (CCCC)vs › | $330.60M | 0.16% | N/A | N/A | N/A |
Debt/Assets
23.6%
Debt/Equity
N/A
Current Ratio
0.34
Interest Coverage
-0.4x
Formula: Debt/Assets = Total Debt / Total Assets × 100
Debt/Assets vs Debt/Equity:
Industry context matters: Capital-intensive industries (utilities, real estate) typically have higher Debt/Assets ratios than tech companies.
Debt/Assets ratio shows what percentage of a company's assets are financed by debt. Compare the current value with the historical chart and peer group to understand leverage over time.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | DEBT TO ASSETS RATIO |
|---|---|
| 2026-06-30 | 23.57% |
| 2026-03-31 | 163.29% |
| 2025-12-31 | 147.66% |
| 2025-09-30 | 19.57% |
| 2025-06-30 | 48.88% |
| 2025-03-31 | 45.98% |
| 2024-12-31 | 41.93% |
| 2024-09-30 | 176.36% |
| 2024-06-30 | 27.66% |
| 2024-03-31 | 135.53% |
| 2023-12-31 | 29.69% |
| 2023-09-30 | 26.54% |
| 2023-06-30 | 22.77% |
| 2023-03-31 | 21.25% |
| 2022-12-31 | 18.96% |
| 2022-09-30 | 18.45% |
| 2022-06-30 | 17.58% |
| 2022-03-31 | 14.57% |
| 2021-12-31 | 12.51% |
| 2021-09-30 | 12.48% |
| 2021-06-30 | 159.18% |
| 2021-03-31 | 127.00% |
| 2020-12-31 | 25.98% |
| 2020-09-30 | 17.97% |
| 2020-06-30 | 20.09% |
| 2020-03-31 | 16.36% |
| 2019-12-31 | 15.06% |
| 2019-09-30 | 13.39% |
| 2019-06-30 | 10.74% |
| 2019-03-31 | 8.48% |
| 2018-12-31 | 9.79% |
| 2018-09-30 | 10.12% |
| 2018-06-30 | 9.89% |
| 2018-03-31 | 9.87% |
| 2017-12-31 | 117.79% |
| 2017-09-30 | 95.97% |
| 2017-06-30 | 78.57% |
| 2017-03-31 | 66.07% |
| 2016-12-31 | 83.25% |
| 2016-09-30 | 72.30% |
| 2016-06-30 | 62.24% |
| 2016-03-31 | 53.50% |
| 2015-12-31 | 47.26% |
| 2015-09-30 | 45.63% |
| 2015-06-30 | 6.34% |
| 2015-03-31 | 9.80% |
| 2014-12-31 | 8.09% |
| 2014-09-30 | 7.66% |
| 2014-06-30 | 7.41% |
| 2014-03-31 | 8.64% |
| 2013-12-31 | 25.45% |
| 2013-09-30 | 24.76% |
| 2013-06-30 | 43.20% |
| 2013-03-31 | 118.35% |
| 2012-12-31 | 103.59% |
| 2012-09-30 | 110.18% |
| 2012-06-30 | 105.82% |
| 2012-03-31 | 100.30% |
| 2011-12-31 | 166.22% |
| 2011-09-30 | 127.69% |
| 2011-06-30 | 137.66% |
| 2011-03-31 | 109.24% |
| 2010-12-31 | 110.64% |
| 2010-09-30 | 135.58% |
| 2010-06-30 | 117.18% |
| 2010-03-31 | 127.66% |
| 2009-12-31 | 108.21% |
| 2009-09-30 | 93.69% |
| 2009-06-30 | 123.51% |
| 2009-03-31 | 135.53% |
| 2008-12-31 | 119.38% |
| 2008-09-30 | 125.82% |
| 2008-06-30 | 109.01% |
| 2008-03-31 | 128.78% |
| 2007-12-31 | 174.12% |
| 2007-09-30 | 145.33% |
| 2007-06-30 | 138.48% |
| 2007-03-31 | 119.87% |
| 2006-12-31 | 103.47% |
| 2006-09-30 | 84.38% |
| 2006-06-30 | 74.07% |
| 2006-03-31 | 62.72% |
| 2005-12-31 | 4.00% |
| 2005-09-30 | 45.70% |
| 2005-06-30 | 40.04% |
| 2005-03-31 | 36.12% |
| 2004-12-31 | 7.46% |
| 2004-09-30 | 7.45% |
| 2004-06-30 | 7.57% |
| 2004-03-31 | 7.79% |
| 2003-12-31 | 11.33% |
| 2003-09-30 | 8.13% |
| 2003-06-30 | 0.18% |
| 2003-03-31 | 0.21% |
| 2002-12-31 | 0.62% |
| 2002-09-30 | 1.15% |
